What Are the Most Commonly Reported Complications With Cosmetic Botulinum Toxin Type A Treatments?

Area of Science:

• Dermatology
• Cosmetic Procedures
• Pharmacovigilance

Background:

• Botulinum toxin type A (BTX-A) is widely used for cosmetic purposes.
• Understanding the safety profile and common adverse events is crucial for patient care and informed consent.

Purpose of the Study:

• To identify and analyze the most frequently reported complications associated with cosmetic BTX-A treatments.
• To investigate factors influencing the occurrence of serious adverse events.

Main Methods:

• A cross-sectional review of FDA Adverse Event Reporting System data from January 2014 to September 2019.
• Analysis included reports for Botox, Dysport, Xeomin, and Jeuveau used in cosmetic procedures.
• Patient demographics, treatment details, and reported reactions were analyzed using multivariate logistic regression.

Main Results:

• Over 10,000 reports detailed nearly 30,000 adverse events.
• The most common reactions were pain, swelling, and eyelid/brow ptosis.
• Serious outcomes occurred in 13.5% of patients and were associated with older age, heavier weight, and specific symptoms like headache and vision changes, but not with pain, swelling, or ptosis.

Conclusions:

• While local complications like pain and swelling are frequent, they are not associated with serious patient outcomes.
• Constitutional symptoms reported after BTX-A treatment warrant careful consideration.
• Providers should educate patients and address misinformation regarding potential adverse events.